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Abstract: Atherosclerosis is a chronic, inflammatory disease that mainly affects the arterial intima.
The disease is more prevalent in middle-age and older individuals with one or more cardiovascular risk
factors, including dyslipidemia, hypertension, diabetes, smoking, obesity, and others. The beginning
and development of atherosclerosis has been associated with several immune components, including
infiltration of inflammatory cells, monocyte/macrophage-derived foam cells, and inflammatory
cytokines and chemokines. Mesenchymal stem cells (MSCs) originate from several tissue sources
of the body and have self-renewal and multipotent differentiation characteristics. They also have
immunomodulatory and anti-inflammatory properties. Recently, it was shown that MSCs have
a regulatory role in plasma lipid levels. In addition, MSCs have shown to have promising potential in
terms of treatment strategies for several diseases, including those with an inflammatory component.
In this regard, transplantation of MSCs to patients with atherosclerosis has been proposed as a novel
strategy in the treatment of this disease. In this review, we summarize the current advancements
regarding MSCs for the treatment of atherosclerosis.
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1. Introduction
Atherosclerosis is a vascular disease that can progress to the point of occlusion of the arterial
lumen and thus, can possibly cause several critical complications, such as coronary artery disease and
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myocardial infarction [1–3]. Among the risk factors for atherosclerosis, hypertension, dyslipidemia,
diabetes, obesity, and smoking have particularly detrimental impacts [4,5]. Atherosclerosis is a leading
cause of mortality around the world despite a lot of efforts in the management and treatment of
cardiovascular risk factors [6]. The pathogenesis of atherosclerosis is complex and has been primarily
attributed to lipoprotein accumulation in the subendothelial space, activation or dysfunction of
endothelial cells (ECs), infiltration of monocytes and macrophages, and their subsequent transformation
into foam cells, which is triggered by oxidized low-density lipoproteins (ox-LDLs) [7–10]. Innate
immune components participate in cholesterol uptake via pattern recognition receptors (PRRs), but they
also participate in EC dysfunction and the development of foam cells [11]. Moreover, for participants in
adaptive immunity, primarily T cells, which are locally activated in the intima, initiate an inflammatory
response and, therefore, participate in further worsening of the development of atherosclerotic
lesions [12,13]. As a consequence, therapeutic strategies aimed at immunosuppression and controlling
the inflammatory response may be promising in the management of atherosclerotic complications [14,15].
In this context, it was postulated that not all the benefits of statins, the mainstay of treatment in patients
with atherosclerotic cardiovascular disease, can be attributed to the cholesterol-lowering action of these
drugs. Statins also possess pleiotropic effects [16–21], particularly anti-inflammatory properties [22,23],
which contributes to the reduction of cardiovascular events. A more relevant piece of evidence was
provided by the CANTOS trial, in which canakinumab, a monoclonal antibody against interleukin
(IL)-1β, was efficacious in lowering cardiovascular events in a lipid-independent manner [24].
Recent directions of research have been concentrated on cell-based therapies. Mesenchymal stem
cells (MSCs) are regarded as the first choice of stem cells for use in regenerative medicine [25]. MSCs
have been obtained from various tissues, including the brain, heart, and kidney [26,27]. The main
reasons that MSCs are candidates for cell therapy is their well-established ability to differentiate
into different cell types and their possibility of in vitro expansion. After in vitro intervention and
re-implantation in the body, MSCs develop the ability to suppress various components of the immune
system and its response.
Recently, it was reported that MSCs can function as protectors against inflammation [28,29].
Thus, for instance, the adoptive transfer of MSCs was proposed as a novel therapeutic tool to treat
atherosclerosis due to their ability to modulate and attenuate the inflammation, which is associated
with atherosclerosis [30]. A better understanding of the functions of MSCs in animal models of
atherosclerosis, as well as of the mechanisms underlying their therapeutic potential, should encourage
further investigation of MSCs in well-designed clinical trials and identification of their possible
application in clinical practice.
2. Characteristics of MSCs
MSCs were first recognized in the stromal matrix of the bone marrow [31,32]. The understanding
of the characteristics and localization of MSCs in the human body is still incomplete. In addition
to bone marrow, MSCs have also been found in tissues such as cord blood, placenta, amniotic fluid,
skeletal muscle, heart, synovial tissue, adipose tissue, pancreas, and circulating blood [33,34]. It has
been supposed that all human body organs, including connective tissues, also contain MSCs [35].
From an embryological perspective, MSCs are considered to be primitive cells that originate from the
mesodermal germ layer. They are regarded as progenitors cells that can differentiate and develop
into several tissue types, such as connective tissue, skeletal muscle cells, and cells related to the
vascular system. MSCs can also develop into mesodermal cell lineages, including bone, cartilage,
and fat. In fact, they can also develop into endodermic and neuroectodermic lineages [36,37]. Due
to their suggested potential in self-renewal and differentiation, bone marrow-derived stromal cells
were first named as stem cells but were later called MSCs [38], which has caused some problems with
this inconclusive nomenclature [39]. Among stem cells, MSCs have become the first and best choice
for regenerative medicine because they are easy to obtain and harvest, they exhibit rapid ex vivo
proliferation, and they have the potential for autologous transplantation [28,40]. MSC involvement in
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the etiopathogenesis of immunology-based diseases and their ability to modulate the immune response
make MSCs an intriguing cell line of which its therapeutic applications are progressively increasing
with the idea to control inflammation-related disorders [41–43].
3. Origin of MSCs
The extraction of MSCs is less invasive than other stem cell types [26]. MSCs have plasticity for
development into lineages of different tissue types, either within or across germ lines [44], and bone
marrow-derived MSC (BM-MSCs) have the highest level of lineage plasticity [45]. Most preclinical trials
have been performed using BM-MSCs for atherosclerosis treatment. However, bone marrow might not
represent the most appropriate source for therapeutic applications. This is because the harvesting of
bone marrow requires invasive procedures and it yields a low supply of cells. Furthermore, the count,
differentiation capacity, and lifespan of BM-MSCs decreases with patient age [46,47]. Two other
alternative sources for harvesting MSCs include adipose tissue and umbilical cord (UC) blood, which
have drawn significant attention in the last several decades [48,49]. MSCs obtained from adipose
tissue have become attractive since adipose tissue can be collected easily and it provides a rich supply
of cells with satisfactory proliferative capacity in vitro [50]. MSCs obtained from the adipose tissue
and bone marrow are similar with respect to their ability for expansion and differentiation, as well as
their immunophenotypes [51], but UC-derived MSCs (UC-MSCs) were just once used in experiments
concerning atherosclerosis. MSCs isolated from dental pulp have not been used for atherosclerosis
experiments [52]. Also, UC blood and Wharton’s jelly are rich sources of MSCs [53,54].
4. Colonization and Migration of MSCs
The initial key step for MSCs targeting other tissues and organs is their mobilization from
the source organs. It has been shown that endogenous MSCs can be mobilized from the source
tissues to the peripheral blood during various conditions such as physiological stress, hypoxia, and
inflammation [55,56]. The precise mechanisms of MSC migration to the target tissues are not fully
explained. However, it is known that MSCs normally migrate to and mediate repair in damaged
tissues. The wound healing function of MSCs starts when the cells migrate towards wounded sites and
is triggered by inflammatory signals [57]. The migration of MSCs is modulated by mediators produced
and released by other MSCs which affect several receptors and signaling pathways, such as growth
factor receptors, G-protein coupled receptor (GPCR), vascular endothelial growth factor/vascular
endothelial growth factor receptor (VEGF/VEGFR), stem cell factor-tyrosine kinase receptor (SCF-c-Kit),
stromal cell-derived factor-1 (SDF-1)/CXC chemokine receptor-4 (CXCR4), hepatocyte growth factor
(HGF/c-Met), platelet-derived growth factor/platelet-derived growth factor receptor (PDGF/PDGFR),
monocyte chemoattractant protein-1/CC chemokine receptor 2 (MCP-1/CCR2), and high mobility
group box 1/receptor of advanced glycation end products (HMGB1/RAGE) [58,59]. SDF-1 and its
receptor, CXCR4, are the main mediators of stem cell recruitment to a tumor microenvironment.
Studies that inhibited the function of either SDF-1 or CXCR4 have indicated a crucial role of these
molecules in the migration of stem cells [60–62]. CXCR4 and SDF-1 blockades in animal models
culminates in a remarkable decrease in the migration potential and the migration rate of transplanted
stem cells to sites of demyelination, suggesting that the SDF-1/CXCR4 signaling pathway is critical for
effective stem cell therapy [62]. Moreover, simultaneous blocking of both CXCR4 and transforming
growth factor (TGF)-β receptor demonstrated that CXCR4 is necessary for colonization of MSCs in
tumors, differentiation to myofibroblasts, and MSC survival [63,64]. MSCs express several chemokine
receptors, including CXCR1, CXCR3, CXCR4, CXCR5, CXCR6, CCR1, CCR2, CCR3, CCR4, CCR5, and
CCR9 [65]. Chemokines such as chemokine (C-X-C motif) ligand (CXCL) 12, CXCL13, CXCL16, and
their corresponding receptors, are involved in the bidirectional migration of MSCs to the BM where
they can create a BM niche and subsequently migrate from the BM into the systemic circulation. On the
other hand, various other specific chemokines and their receptors participate in the unidirectional
migration of MSCs. CXCL16 plays a critical role in the homing of MSCs to the BM, while chemokine
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(C-C motif) ligand (CCL) 22 has the most powerful chemotactic influence in terms of the release and
movement of MSCs from the bone marrow into the circulation [66,67].
Cell receptor transactivation seems to play a role in migration and is also involved in physiological
processes like apoptosis. However, impaired cell receptor transactivation predisposes human cells to
pathological conditions. Transactivation of several growth factor receptors, such as epidermal growth
factor receptor (EGFR), by GPCRs has been reported to be involved in multiple cellular activities,
including responsiveness to cytokines and growth factors [68–71]. Studies have suggested that the
mechanism of receptor transactivation is mediated by the stimulation of membrane-tethered growth
factors, such as EGFR, by interacting with GPCRs like CXCR4 [72]. EGFR transactivation is associated
with the production of matrix metalloproteinases (MMPs), such as MMP-2 and MMP-9 [73,74], which
are enzymes with proteinase activity and are needed to process proteins, such as growth factors,
cytokines, and adhesion molecules. MMP-1 is required for the migration of MSCs through bone
marrow endothelium [75–77]. Increased levels of MMP-2 are responsible for C1q complement-mediated
migration of UC-MSCs into the site of injury [78]. MSCs can migrate to tissue sites that have previously
been irradiated. Local irradiation was shown to increase the specificity of MSCs for migration
and implantation [79]. Based upon all these data, the available evidence supports the rationale for
developing new therapeutic approaches that involve MSCs.
5. Immunomodulatory Properties of MSCs
The immunosuppressive properties of MSCs have been confirmed by a number of studies
(Figure 1). Since MSCs can change the behavior of T cells, they have been tested for treating severe graft
versus host disease (GVHD) [80]. For example, CD4+ and CD8+ T cells are prevented from proliferation
and activation by MSCs [81–83]. Most of the immunomodulatory activity of MSCs has been attributed
to the enzyme indoleamine-pyrrole-2-3-dioxygenase (IDO) [84]. By regulating tryptophan depletion
and the accumulation of mediators like kynurenines, IDO can inhibit the proliferation of immune
cells [85,86]. MSCs have been shown to stop the cell cycle of B cells in the G0/G1 phase as well
as to reduce the chemotactic activity of B cells. MSCs can also prevent dendritic cells (DCs) from
maturation, leading to a decreased presentation of antigens and costimulatory molecules required
for T cell activation [87]. MSCs can also reduce the expression of activating receptors on natural
killer (NK) cells, including NKG2D, NKp30, and NKp44 [88,89]. It has also been shown that MSCs
modulate the cytokine secretion profile of immune cells, such as T cells, DCs, and NK cells [90].
MSCs can also decrease interferon (IFN)-γ secretion from Th1 cells and NK cells, they can decrease
the secretion of tumor necrosis factor (TNF)-α from DCs type 1 (DC1), increase the secretion of IL-4
from Th2 cells, and increase IL-10 secretion from DC2. In vitro studies have indicated that MSCs can
inhibit the differentiation of naive CD4+ T cells into Th17 cells. Therefore, MSCs can also regulate the
production of IL-17, IL-22, TNF-α, and IFN-γ [91]. BM-MSCs have been reported to modulate T and B
cells by reducing the production of proinflammatory cytokines, such as TNF-α, IFN-γ, and IL-2 [92].
TNF-α-stimulated gene-6 (TSG-6), a strong anti-inflammatory mediator, is also secreted by MSCs [93].
MSCs also express toll-like receptors (TLRs), including TLR3 and TLR4, which are involved in the
regulation of their anti-inflammatory functions [94].
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Figure 1. Schematic illustration of anti-inflammatory and immunomodulatory characteristics of 
mesenchymal stem cells (MSCs) in regulating immune cells. MSCs can suppress the differentiation of 
Th1 and Th17 cells and the secretion of cytokines specific to these cells. MSCs induce the development 
of Th2 and regulatory T (Treg) cells, which in turn produce immunosuppressive mediators. MSCs 
orchestrate the balance between the development of M1 and M2 macrophages. M1 macrophages 
usually produce immunostimulatory cytokines, while the major cytokine profile of M2 macrophages 
has immunosuppressive properties. Type 2 dendritic cells (DCs) are developed under the impression 
of MSCs and produce IL-10. MSCs prevent the transformation of macrophages into foam cells in 
atherosclerosis. Foam cells are low-density lipoprotein (LDL)-laden macrophages contributing to 
atherosclerosis through the formation of plaques. The foam cell formation is a consequence of the 
disruption of balance between cholesterol uptake and cholesterol efflux in macrophages present at 
intima. MSCs, however, have the potential to prohibit foam cell formation via the reduction of 
cholesterol uptake and up-regulation of IL-10, eliminating a risk factor for atherosclerosis 
development. 
6. Pathophysiology of Atherosclerosis and the Role of Inflammation 
Atherosclerosis is an inflammatory arterial disease which is initiated by dyslipidemia, arterial 
hypertension, smoking, obesity, and other risk factors [95–97]. Each step of the atherosclerotic process, 
from the beginning of the plaque development to its rupture, is accompanied by inflammation [98,99]. 
During the initial events of atherosclerosis, ox-LDLs are trapped in the vessel wall, resulting in the 
dysfunction of the endothelial cells [100,101]. Later, adhesion molecules, for example, selectins and 
integrins, are overexpressed on leukocytes, culminating in increased adhesion, rolling, and migration 
of inflammatory cells into the subendothelial region of the arterial wall [102–104]. The next step in 
the atherogenic cascade is the increased infiltration of T cells, monocytes, and neutrophils across the 
vessel wall through interendothelial junctions. In the subendothelial region, macrophages ingest 
lipoproteins and are overstuffed with lipids, and are then transformed into foam cells, which then 
produce several inflammatory mediators [105,106]. When immune cells and lipid molecules 
accumulate in the intima, the early phase of plaque develops, which is called fatty streak. Endothelial 
injury progresses and may be accompanied by endothelial progenitor cell homing in an attempt to 
repair the injured endothelium. Foam cells and extracellular lipids form a core of the developing 
plaque, which is then covered with a cap of collagen-rich matrix and smooth muscle cells [8,107]. By 
the engagement of TLRs on the macrophages, these cells are activated and inflammatory cytokines and 
mediators are subsequently produced and released. The activation of CD4+ T cells plays a significant role 
in the development of atherosclerosis. The depletion of T cells causes a reduction of the atherosclerotic 
lesion size [108]. Th1 is the most prevalent subset of T cells in atherosclerotic lesions and is involved 
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cholesterol uptake and up-regulation of IL-10, eliminating a risk factor for atherosclerosis development.
6. Pathophysiology of Atherosclerosis and the Role of Inflammation
Atherosclerosis is an inflammatory arterial disease which is initiated by dyslipidemia, arterial
hypertension, smoking, obesity, and other risk factors [95–97]. Each step of the atherosclerotic process,
from the beginning of the plaque development to its rupture, is accompanied by inflammation [98,99].
During the initial events of atherosclerosis, ox-LDLs are trapped in the vessel wall, resulting in the
dysfunction of the endothelial cells [100,101]. Later, adhesion molecules, for example, selectins and
integrins, are overexpressed on leukocytes, culminating in increased adhesion, rolling, and migration
of inflammatory cells into the subendothelial region of the arterial wall [102–104]. The next step in
the atherogenic cascade is the increased infiltration of T cells, monocytes, and neutrophils across the
vessel wall through interendothelial junctions. In the subendothelial region, macrophages ingest
lipoproteins and are overstuffed with lipids, and are then transformed into foam cells, which then
produce several inflammatory mediators [105,106]. When immune cells and lipid molecules accumulate
in the intima, the early phase of plaque develops, which is called fatty streak. Endothelial injury
progresses and may be accompanied by endothelial progenito cell h ming in an attempt to repair the
injured endothelium. Foam cells and extracellular lipids form a core of the developing plaque, which
is then covered with a cap of collagen-rich matrix and smooth muscle cells [8,107]. By the engagement
of TLRs on the macrophages, these cells are activated nd inflammatory cytokines and m diators
are subsequently produced an release . The activation of CD4+ T cells plays a significant rol in
the development of atherosclerosis. The depletion of T cells causes a reduction of the atherosclerotic
lesion size [108]. Th1 is the most prevalent subset of T cells in atherosclerotic lesions and is involved in
the production of inflammatory mediators like IFN-γ [109,110]. On the other side, IFN-γ modulates
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inflammation in the vessel wall by promoting the activation of antigen-presenting cells, decreasing the
production of collagen by modified smooth muscle cells, upregulating lipid ingestion by macrophages,
and upregulating adhesion molecules on ECs. These events are followed by the infiltration of
inflammatory immune cells from blood to the lesions [111]. The persistent infiltration of leukocytes to
the atherosclerotic lesion sites maintains a local state of low-grade inflammation.
Because of the critical function of inflammation in the initiation and perpetuation of atherosclerosis,
the engraftment of MSCs, which have the potential to regulate and control inflammation, has been
extensively investigated as a potential therapeutic tool for treating atherosclerosis. Allogeneic MSCs
have important characteristics, which include the suppression of T cell proliferation and suppression
of the immune response elicited from T cells. This suggests that transplantation of allogeneic MSCs
may represent a beneficial therapeutic approach for atherosclerosis [112,113]. Many investigations on
animal models have documented that MSCs can act against atherosclerosis. In most of these animal
models, atherosclerosis was induced by a high-fat diet in either apolipoprotein E (ApoE) or low-density
lipoprotein receptor (LDLR) knockout mice. In most of these animal studies, MSCs were obtained
from bone marrow. Nevertheless, UC-MSCs and skin-derived MSCs (S-MSCs) can also be used for
analyzing their possible atheroprotective effects.
7. Modulation of Inflammatory Mediators by MSCs during Atherosclerosis
Many studies have confirmed that the protective properties of MSCs on atherosclerotic
lesions are based predominantly upon their secretion of various anti-inflammatory mediators [114].
Transplantation of BM-MSCs in the atherosclerotic lesions of various animals (Table 1) resulted in
an overproduction of anti-inflammatory cytokines, including IL-10 and TGF-β1, while the production
of pro-inflammatory cytokines, such as IL-1β, IL-6, and TNF-α, were reduced [115]. TGF-β1 secretion
by MSCs causes the induction of CD4+CD25+Foxp3+ regulatory T (Treg) cells [116] and also suppresses
the proliferation of NK cells [117]. Additionally, engraftment of MSCs causes a reduction in the serum
levels of CCL2, which is a chemokine that plays a role in the activation and recruitment of mononuclear
cells [118]. MSC also suppress the differentiation of T cells. S-MSC therapy, both in vivo and in vitro, is
also involved in the attenuation of inflammation by inhibiting the production and release of TNF-α and
stimulating IL-10 release [119]. MSCs can also inhibit the expression and function of NF-κB [120–122].
In fact, there is also evidence demonstrating the downregulation of NF-κB in atherosclerotic lesions
after MSC engraftment [123].
Table 1. Animal studies exploring the therapeutic potential of mesenchymal stem cells in the treatment
of atherosclerosis.
Animal Model Cell Source Administration Route Consequence Reference
New Zealand
rabbits Bone marrow Intravenous
Increased: TSG-6, IL-10, hs-CRP, TNF-α,
IL-6, NF-κB
Decreased: Apoptosis, MMPs
[123]
New Zealand
rabbits Bone marrow Intra-arterial
Increased: Collagen fibers
Decreased: MMPs, PAI-1, hs-CRP [124]
ApoE−/− mice Bone marrow Intravenous Increased: TregsDecreased: SRA, CD36 [115]
ApoE−/− mice Bone marrow Intravenous Increased: eNOS, IL8, MIP-2 [125]
ApoE−/− mice Skin Intravenous Increased: IL-10, PGE2Decreased: NF-κB, TNF-α [119]
LDLR−/− mice Bone marrow Intravenous
Increased: Tregs
Decreased: CD4+ T cells, CCL2, IFN-γ,
monocytes, TNF-α, serum cholesterol
[118]
Albino rats Cord blood Intravenous Increased: iNOS [126]
TSG-6: TNF-α-stimulated gene-6; IL-10: interleukin-10; hs-CRP: high-sensitivity C-reactive protein; TNF-α: tumor
necrosis factor-α; IL-6: interleukin-10; iNOS: inducible nitric oxide synthase; SRA: class A scavenger receptor; eNOS:
endothelial nitric oxide synthase; PGE2: prostaglandin E2; IL-8: interleukin-8; MIP-2: macrophage inflammatory
protein 2; CCL2: chemokine (C-C motif) ligand 2; IFN-γ: interferon-γ; Treg: regulatory T cell; MMP: matrix
metalloproteinase; PAI-1: plasminogen activator inhibitor-1.
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MSCs also produce and release immunomodulatory mediators, such as prostaglandin E2 (PGE2),
IDO, and TSG-6 [127]. Differentiation of Th17 cells, which produce inflammatory cytokines, is inhibited
by IDO through tryptophan depletion [86]. IDO also reduces the proliferation and cytotoxic activity
of NK cells, as well as prevents the maturation, activation, and function of DCs [128]. It has been
reported that PGE2 promotes Treg cell development, reduces T cell proliferation, and stimulates
the production of IL-4 and IL-10 [129]. Cells and tissues normally do not express TSG-6. However,
TSG-6 is upregulated when cells are stimulated by pro-inflammatory cytokines such as IL-1, IL-6,
and TNF-α [130,131]. TSG-6 is involved in a feedback loop or mechanism to prevent the remodeling
of extracellular matrix by a reduction in the expression of inflammatory mediators, suppression of
neutrophil recruitment, and inhibition of the activity of plasmin [132,133]. A recently published
study demonstrated that MSCs-exosomes ameliorated atherosclerosis in ApoE−/− mice and promoted
M2 macrophage polarization in the atherosclerotic plaque through the miR-let7/HMGA2/NF-κB
pathway and that they suppressed macrophage infiltration via the miR-let7/IGF2BP1/PTEN pathway
in the atherosclerotic plaque. The conclusion was that MSCs-exosomes can affect inflammation in
atherosclerotic plaque [129]. Recently, it has been shown that human amnion mesenchymal stem
cells (hAMSCs), which are a particular population of MSC and have immunomodulatory abilities,
suppressed the phosphorylation of p65 and inhibitor of κB-α, suggesting that the NF-κB pathway was
involved in the hAMSCs-mediated suppression of the immune response [130,131].
8. Prospects for MSC-Based Therapy of Atherosclerosis
8.1. MSCs and the Improvement of Endothelial Function during Atherosclerosis
Endothelial dysfunction is considered to be the initial step in the development of atherosclerosis,
which promotes the accumulation of lipid droplets, the infiltration of macrophages, the development
of foam cells, and, subsequently, the recruitment of platelets and T cells [134]. The endothelium
is a complicated organ with both endocrine and paracrine characteristics that are involved in the
control of vascular homeostasis. Vascular nitric oxide (NO) is produced by endothelial nitric oxide
synthase (eNOS) [135,136]. As a vasodilator, NO enhances the level of cyclic guanosine monophosphate
(cAMP) in smooth muscle cells and at the same time, suppresses the adhesion of leukocytes, limits
platelet aggregation, and prevents the proliferation of smooth muscle cells. Therefore, NO has
anti-inflammatory properties by restricting the infiltration of leukocytes across the vessel wall [137].
In spite of the ability of ECs to self-repair in the presence of inflammatory stimuli, endothelial repair
could be further stimulated by MSCs. It has been observed that amnion-derived MSCs (A-MSCs) were
able to increase the survival of ECs in vitro by downregulating the level of lactate dehydrogenase
and contributing to the maintenance of the endothelial network [138]. Engraftment of allogeneic
BM-MSCs was reported to ameliorate atherosclerosis by repairing the injured endothelium [125].
NO production from ECs is reduced by ox-LDL via the deactivation of the Akt/eNOS function and
stimulation of eNOS cleavage [139]. However, when MSCs were cocultured with endothelial cells,
ox-LDL did not have the same effects on these cells [140]. It appears that the beneficial influence of
MSCs on endothelial cells (via the activation of the Akt/eNOS pathway) is mediated by an increased
production of IL-8 and macrophage inflammatory protein (MIP)-2. This observation was confirmed
when neutralization antibodies against IL-8 or MIP-2 were evaluated, which blocked the effects of
MSCs on ox-LDL-exposed ECs [125]. It has been shown recently that differentiation of BM MSCs into
endothelial cells in vitro might have beneficial effects and could have an application in the treatment
of atherosclerotic lesions [125]. Skin-derived MSCs have also been used in experiments trying to find
a treatment for atherosclerosis [119]. Therefore, by improving the physiological function of endothelial
cells, MSC transplantation could slow down the development of atherosclerosis [125,141].
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8.2. MSCs and Regulatory T Cell Development during Atherosclerosis
Regulatory T cells demonstrate immunosuppressive behavior and modulate the quality and
quantity of the immune response by either direct contact with other cells or by secretion of
immunoregulatory mediators such as IL-10 and TGF-β [142]. Tregs are CD4+CD25+ T cells that
express the forkhead box transcription factor (FOXP3), which is the specific transcription factor that
modulates the development and function of Treg cells [143,144]. Studies have shown that the number
of Treg cells is decreased in atherosclerotic plaques [145,146]. Moreover, when FOXP3 is knocked
down, the progression of atherosclerosis occurs in various animal models [147], suggesting a possible
protective function of Treg cells against atherosclerosis. By suppressing the function of DCs and Th1/Th2
cells, Treg cells have atheroprotective activity in mice with immunodeficiency and hyperlipidemia [148].
In accordance with this, it has been shown that Treg cells produce IL-10 and TGF-β in the atherosclerotic
milieu and, therefore, inhibit the functions of DCs and Th1/Th2 cells [149–152]. Tregs have also been
reported to be able to suppress the expression of MMP-2 and MMP-9, which are important enzymes
that degrade the extracellular matrix and promote the instability of atherosclerotic lesions [153].
Although the application of Treg cells would appear to be promising in the treatment of
atherosclerosis, there are some challenges. Among the most limiting factors is the difficulty in
the efficient separation of Treg’s to achieve a pure or homogeneous population of these cells. To
resolve this problem, MSCs have been suggested to be an adequate alternative cell source. The
application of MSCs could be achieved by promoting the recruitment and development of Treg cells
from an individual patient [124,127]. When MSCs were co-cultured with splenocytes, the number
and function of Treg cells were enhanced. Moreover, MSCs have upregulated both the messenger
RNA (mRNA) and protein expression of FOXP3 in an atherosclerotic animal model [115]. A number
of mechanisms have been proposed regarding the capacity of MSCs to modulate the proliferation
and activation of Treg cells. MSCs also secrete high levels of TGF-β1 to enhance the differentiation
of Treg cells [154]. Another direct cell–cell contact mechanism mediated by MSCs is TLR-mediated
stimulation of Treg cells, which is facilitated by upregulating the levels of the Notch ligand, Delta-like
1 [94]. MSCs induce Treg cells via notch ligand Jagged-1 as well [155]. Monocytes are also important for
MSC-induced development of Treg cells. In fact, MSCs contribute to the differentiation of monocytes
to type 2 macrophages, which have anti-inflammatory characteristics and promote Treg cell generation
by the production of CCL18 [154].
8.3. Recruitment of MSCs into Atherosclerotic Plaques
The commitment of MSCs into effector cells facilitates their capacity to repair injured tissues.
S-MSCs can locate atherosclerotic plaques and are specifically homed closely to macrophages.
Carboxyfluorescein succinimidyl ester-labeled mouse MSCs, 7 days after an injection, reside in regions
near macrophages in the endothelium affected by atherosclerotic lesions [119,125]. Transplanted
BM-MSCs reside in regions of ruptured plaques and then differentiate into collagen fibers and ECs [124].
After four weeks of MSC engraftment, 5-bromo-2′-deoxyuridine (BrdU)-labeled BM-MSCs are found
in the injured areas of the endothelium. Several mediators and receptors are involved in regulating
the migration and differentiation of stem cells to the site of vascular injury, for example, β1- and
β2-integrins, α4 integrin, P-selectin glycoprotein ligand-1, and CXC chemokine receptor-2 and -4
(CXCR2 and CXCR4) [156,157]. During vascular repair, the direct interaction between progenitor
cells and platelets enhances MSC activation, adhesion, chemotaxis, and their possibility to transform
into mature ECs [158]. It has to be stressed that more recent studies indicate that a very limited
number of MSCs are retained after treatment. It seems that the beneficial effect of MSCs appears to be
predominantly due to paracrine signaling mechanisms, including by exosomes transporting various
proteins and non-coding RNAs such as micro-RNAs and lncRNAs [154].
Macrophages are the major players in atherosclerosis during foam cell formation and are
responsible for plaque stability. It has been shown that MSCs can modulate macrophages, for instance
they can reprogram this type of cell into anti-inflammatory phenotypes, M2 macrophages [159,160].
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However, it is still not clear whether the macrophage phagocytic capacity is weaker or stronger when
co-cultured with MSCs, and the signaling pathways by which MSCs modulate macrophage needs
further research.
8.4. The Role of MSCs in Modulating Lipid Levels
Dyslipidemia is the main risk factor for the onset and progression of atherosclerosis [161].
The indirect effect of MSCs on cholesterol metabolism via immune modulation has been confirmed.
A relationship between cholesterol metabolism and immune cells has also been described. In both
LDLR−/− mice on a high-fat diet and ApoE−/− mice on a normal chow diet, T and B cell deficiency
decreased serum lipoproteins, particularly the apoB-rich lipoproteins [162]. Following 5 weeks
of treatment with MSCs in mice, the inflammatory state was modulated and serum cholesterol
levels were considerably reduced due to a reduction in very low density lipoprotein (VLDL)
levels [118]. A significant reduction of lipoprotein lipase was observed in the liver of MSC-treated
mice, which decreases VLDL katabolism by decreasing the breakdown of triglycerides into free fatty
acids, which results in less availability of free fatty acids for VLDL particles synthesis by hepatocytes.
Furthermore, decreased activation of Kupffer cells indirectly affects VLDL metabolism in MSC-treated
mice because in physiological conditions, Kupffer cells, by releasing different mediators, promote
secretion of VLDL from hepatocytes [163]. Additionally, lipoprotein lipase insufficiency in Kupffer
cells attenuates their uptake of ox-LDL or VLDL, thus acting antiatherosclerotic [159,160]. All these
data suggest that MSCs can decrease plasma VLDL levels. Interestingly, it has been shown that
TNF-α, which is downregulated in splenocyte and MSC co-cultures, upregulates sterol response
element binding protein -1c (SREBP-1c), which promotes the generation of VLDL particles [164].
In contrast, in LDLR−/− mice, IL-10 upregulation decreases serum cholesterol levels, primarily because
of decreased VLDL levels [165]. It has been shown that induced pluripotent stem cells-derived
MSCs (iPSC-MSCs/iMSCs) have longer survival times, stronger proliferative capacity and are more
stable than bone marrow-MSCs, and that they can also, apart from decreasing serum cholesterol and
inflammatory response, decrease the expression of Notch 1. Notch1 is a receptor in the Notch signaling
pathway, which is a highly conserved pathway that is associated with many cellular processes, such as
differentiation, proliferation, and apoptosis [166]. It is important to know which type of MSCs might be
the best to prevent atherosclerosis when macrophages are exposed to atherogenic ox-LDL. It has been
shown that adipose tissue MSCs co-cultured with M1 foam macrophages when treated with ox-LDL
would cause similar or improved anti-inflammatory effects when compared with BM-MSCs [167].
8.5. Stability of Atherosclerotic Plaque and MSCs
Depending on the internal environment, atherosclerotic plaques can be stable or unstable. It has
been suggested that plaque regions with a large lipid core, a large number of macrophages, and a thin
fibrous cap are more susceptible to rupture, but matrix-degrading proteases from foam cells induced by
inflammatory cells as well as immature neovessels sprouting into the atherosclerotic lesion are also very
important for plaque stability [168]. Rupture of the atherosclerotic plaque significantly increases the risk
of myocardial infarction, ischemic stroke, and acute coronary syndrome [169,170]. An increasing body
of clinical evidence demonstrates that vulnerability, rather than the plaque size, is closely associated
with cardiovascular prognosis [171,172]. The ability of allogeneic MSCs in repairing ruptured lesions
has been intensively investigated. It appears that MSCs can promote collagen fiber synthesis and
regeneration of the inner endothelial layer of the vessel wall, suggesting their significance in treating
the advanced atherosclerotic lesions [124].
C-reactive protein (CRP) is an important predictive marker of plaque instability. CRP stimulates
chemotaxis of several adhesion molecules to endothelial cells. Moreover, CRP stimulates macrophages
to synthesize and release pro-coagulant and pro-inflammatory factors, exacerbating the inflammatory
state [173,174]. It should also be mentioned that plasminogen activator inhibitor-1 (PAI-1), which is
primarily involved in fibrinolysis, is an important risk factor for thrombotic disorders and is one of the
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several biomarkers of tissue injury [175]. MSC engraftment significantly reduced the expression of the
key biomarkers of tissue injury, such as PAI-1, CRP, and MMPs, in an atherosclerosis rabbit model [124].
TNF-α directly influences plaque stability and stimulates cell necrosis and thrombosis by recruitment
and accumulation of inflammatory cells in atherosclerotic regions [176]. On the other hand, IL-10, as an
anti-inflammatory factor, induces the proliferation of smooth muscle cells and inhibits inflammatory
cell accumulation, thereby promoting atherosclerotic lesion stability [177,178]. In an atherosclerotic
rabbit model, MSC transplantation stabilized vulnerable plaques via the reduction of IL-6 and TNF-α
and an increase of IL-10. [123]. MSC engraftment downregulated the expression of MMP-9, MMP-1,
and MMP-2 in atherosclerotic lesions. These data suggest that MSCs, by reducing the MMP production,
could modify plaque vulnerability and decrease local collagen degradation.
Another factor which is involved in atherosclerotic plaque formation is cell apoptosis [179,180].
It has previously been established that the apoptosis of macrophages, vascular ECs, and vascular
smooth muscle cells is involved in the generation, progression, and rupture of atherosclerotic
lesions [181]. Interestingly, MSC engraftment considerably reduces the number of apoptotic cells in
atherosclerotic lesions, suggesting that MSCs can further promote plaque stability and decrease the
risk of atherosclerosis [123]. Arterial hypertension is not only a cardiovascular disease (CVD) risk
factor, but can also influence plaque stability. It has been shown that skin-MSCs attenuated angiotensin
II-induced hypertension by inhibiting Th17 cell differentiation and by modulating macrophage M2
polarization. This suggests that skin-MSCs do not only suppress the formation of the atherosclerosis,
but potentially also have a role in MSC based therapy for hypertension [182].
9. Drawbacks of MSCs Therapy in Atherosclerosis
The safety of MSC engraftment in several preclinical and clinical trials has been shown in small
pilot studies on humans, but not those with atherosclerotic lesions [183–185]. However, the exact dose
range of MSCs for therapeutic use in atherosclerosis has not been well characterized. Nonetheless,
an optimal dose of MSCs for engrafting has been suggested and ranges from 1 to 5 × 106 MSCs per 1 kg
of body weight [186]. In cancer patients, an optimal dose of MSCs has been suggested—for example,
1 × 106 MSCs per 1 kg of body weight in breast carcinoma—and it appears to be well-tolerated [187].
It has to be stressed that a lot is still not known regarding time-dependent effects of using MSCs
to treat atherosclerosis. It is not clear what the short- and long-term effects of using MSCs are.
Nevertheless, in animal models, allogeneic MSCs, despite having low immunogenicity, can be rejected
by the recipient animal [36]. One of the problems with this therapeutic approach to atherosclerotic
lesions is that any MSC-based therapy would surely have systemic effects. Furthermore, while early
phase clinical and preclinical studies have not yet identified any potential complications of MSC
transplantation in humans, tumor development has increasingly been documented in several rodent
models. Chromosomal instability has been found in mouse BM-MSCs, which may act as a trigger
for malignant transformation [188]. Also, BM-MSC transplantation may increase the risk of gastric
cancer [189]. In recent years, a general consensus has been reached that improved manufacturing
conditions, including cell preparation, isolation, culture, and manipulation, can considerably decrease
the tumorigenicity of transplanted MSCs. In fact, the duration of cell harvesting, as well as cell
culture conditions, significantly influence the occurrence of malignancy as an adverse effect [190].
When discussing atherosclerosis and MSCs, some experiments on animal models proved that MSC
can cause calcification and even injure abdominal aorta after bone marrow-MSC administration [191].
There is a number of other potential adverse effects when using MSCs in atherosclerosis treatment [192].
Therefore, further efforts are needed to evaluate the safety of MSC transplantation in the context of
atherosclerosis therapy.
10. Investigation of MSC Potential to Treat Atherosclerosis in the Clinical Setting
Clinical trials evaluating the therapeutic potential of MSCs from diverse sources have mainly been
focused on the assessment of the safety and efficacy of recruiting such cells to treat and/or alleviate
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peripheral arterial disease (PAD) secondary to critical limb ischemia (CLI) and diabetes. The majority
of these studies are still in progress and only a small number of these trials are reported to be completed;
however, no results have been released to date. In the following, we provide some details regarding
the relevant clinical investigations initiated during the last 10 years.
The first clinical trial in this context was started in 2010 including culturing MSCs in the presence
of gold nanoparticles with silica-iron oxide shells and infusion of nanoparticle-bearing cells into
atherosclerotic lesions. The investigation aimed to compare the use of gold nanoparticles with iron
oxide-silica shells with stenting as measures to be taken to circumvent atherosclerosis (NCT01436123).
Although the study was terminated, no results are available.
Another study in 2011 recruiting 25 participants with CLI and PAD aimed to investigate the MSC
ability to treat CLI with autologous MSC administration (NCT01351610). The human BM-CD34-negative
MSCs were intravenously infused and their tolerability and efficacy by the patients were studied.
A trial research was started in 2012 to determine the safety and possibility of three different doses
of mesenchymal-like stem cells called endometrial regenerative cells (ERCs)/intramuscularly derived
menstrual mesenchymal stem cells on 15 CLI patients. The participants are not eligible for surgical
or catheter-based interventions for revascularization. The study includes 10 injections of 2.5, 5, or
10 million MSCs (a total of 25, 50, or 100 million ERC) to the gastrocnemius muscle above the failed
vascular perfusion area (NCT01558908).
An interventional phase I and II clinical trial initiated in 2014 aims to evaluate the safety and
efficacy of UC-MSC injection to alleviate PAD complications in 30 diabetic patients. The participants
were divided into three groups to receive different doses of UC-MSCs, followed by another injection of
the same UC-MSCs dose 4 and 8 weeks after the first infusion (NCT02287831).
In 2015, a phase I clinical trial for analyzing MSC potential in ameliorating diabetic foot ulcers
was designed (NCT02796079). Using autologous BM-MSCs, the investigators evaluate the therapeutic
application of MSC against diabetes-related vascular complications.
Another similar clinical study was established in 2016 to assess the safety of UC-MSC infusion in
around 240 diabetic patients suffering from diabetes-related vascular complications (NCT02834858).
Recruiting 240 diabetic patients with peripheral vascular disease, ischemia, and diabetic foot,
a clinical assessment was performed using adipose-derived MSCs for the evaluation of MSC potential
in healing foot ulcers that resulted from diabetes (NCT02831075).
A phase I clinical trial was recruited in 2016 to investigate the preventive effects of allogenic
BM-MSC intra-muscular administration in areas near the amputation region from wound ischemia
and revision incidence following amputation surgery. The investigation includes 16 patients
with atherosclerotic limb ischemia undergoing semi-elective lower extremity major amputation
(NCT02685098).
An interventional phase II and III clinical trial has been running since 2017 and is aimed to
assess the efficacy, effectiveness, and safety of exposure to allogeneic BM-MSC for angiogenesis
and neovascularization in 60 patients with no-option severe limb ischemia (SLI) (NCT03042572).
The patients receive 30 injections of 5 × 106 BM-MSCs (a total of 150 × 106 BM-MSCs) in 30 different
injection sites in the lower leg of the ischemic extremity.
A 2018-initiated clinical trial was conducted to understand the safety and efficacy of allogenic
ABCB5-positive MSCs at a dose of 150–225 × 106 cells (being administered via 20–30 intramuscular
injections) in treating peripheral arterial occlusive disease (PAOD) (NCT03339973).
A very recent phase II study has commenced on CLI and PAD patients who will be exposed to
autologous adipose-derived stem/stroma cell (ASC) through intramuscular injection (NCT03968198).
11. Conclusions and Future Challenges and Perspectives
MSCs have displayed remarkable beneficial characteristics, which could make them suitable to
being used for several therapeutic purposes, among others, in reducing atherosclerosis. Some of the
advantages of MSCs are the production of mediators which can attenuate inflammation, the potential
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to migrate to sites of arterial injury, and the ability to respond proportionally to the size of the tissue
injury. An important issue concerning the role of MSCs in atherosclerosis treatment is probably the
mechanobiology of MSCs. Considering the hemodynamic nature of the vasculature and the important
role that fluid forces play in the progression of atherosclerosis, the effect of different mechanical stresses
on MSCs could be important [193]. Mechanobiology plays a major role in transducing physical forces
into biochemical modifications that promote different MSCs differentiation pathways and it is well
known that the stiffness of the extracellular matrix (ECM) surrounding MSCs influences the path of
differentiation [194]. Since the type of ECM modulates MSC mechanotransduction, it has recently been
shown that Yes-associated protein (YAP) translocation probably plays a role in this process [195].
The mediators produced and released by MSCs in atherosclerotic lesions contribute to
the modulation of inflammation and can improve the function of the damaged endothelium.
MSC engraftment might provide a novel strategy for the improvement of atherosclerotic lesions
and for the prevention of plaque rupture. A considerable number of experimental in vitro and animal
studies support the idea of a possible clinical application of MSC-based therapy. Therefore, in order to
achieve sustained and long-term beneficial effects of MSCs, additional therapeutic treatment modalities
are required. Based on current evidence, further investigations of MSCs are needed to better understand
the methods required to harvest larger numbers of these cells, as well as techniques of modifying
their biological functions/properties in vitro in order to obtain more effective MSCs. In the near future,
engineering of MSCs to selectively deliver immunosuppressive and anti-angiogenic agents which
would decrease the development of atherosclerotic lesions might be an additional therapeutic solution,
however the role of MSCs in general should be the subject of future investigations because many
questions still need to be answered. One of the biggest challenges is still how to translate the results of
in vitro and animal studies with MSCs into studies on humans with atherosclerotic plaques. Another
challenge is how to target the specific pathways involved in atherogenesis with MSCs and retain MSCs
at the sites of action, i.e., atherosclerotic lesions, without affecting other areas and other mechanisms.
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Abbreviations
MSC mesenchymal stem cell
EC endothelial cell
ox-LDL oxidized low-density lipoprotein
PRRs pattern recognition receptors
IL interleukin
BM-MSC bone marrow-derived mesenchymal stem cell
UC-MSC umbilical cord—derived mesenchymal stem cell
GPCR G-protein coupled receptor
VEGF/VEGFR vascular endothelial growth factor/vascular endothelial growth factor receptor
SCF-c-Kit stem cell factor—tyrosine kinase receptor
SDF-1 stromal cell-derived factor-1
CXCR4 CXC chemokine receptor-4
HGF/c-Met hepatocyte growth factor
PDGF/PDGFR platelet-derived growth factor/platelet-derived growth factor receptor
MCP-1/CCR2 monocyte chemoattractant protein-1/CC chemokine receptor 2
HMGB1/RAGE high mobility group box 1/receptor of advanced glycation end products
TGF-β transforming growth factor-β
CXCL chemokine (C-X-C motif) ligand
CCL chemokine (C-C motif) ligand
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EGFR epidermal growth factor receptor
MMP matrix metalloproteinase
GVHD graft versus host disease
IDO indoleamine-pyrrole-2-3-dioxygenase
DC dendritic cell
NK natural killer
IFN interferon
TNF-α tumor necrosis factor α
DC1 dendritic cell type 1
TSG-6 TNF-α-stimulated gene-6
TLR toll-like receptor
ApoE apolipoprotein E
LDLR low-density lipoprotein receptor
S-MSC skin-derived MSC
Treg cell regulatory T cell
PGE2 prostaglandin E2
hAMSC human amnion mesenchymal stem cell
NO nitric oxide
eNOS endothelial nitric oxide synthase
cAMP cyclic guanosine monophosphate
A-MSC amnion-derived mesenchymal stem cell
MIP-2 macrophage inflammatory protein 2
FOXP3 forkhead box transcription factor
mRNA messenger RNA
BrdU 5-bromo-2′-deoxyuridine
VLDL very low density lipoprotein
iPSC-MSC/iMSC induced pluripotent stem cells- derived mesenchymal stem cell
SREBP-1c sterol response element binding protein-1c
CRP C-reactive protein
PAI-1 plasminogen activator inhibitor-1
CVD cardiovascular disease
PAD peripheral arterial disease
CLI critical limb ischemia
ERC endometrial regenerative cell
SLI severe limb ischemia
PAOD peripheral arterial occlusive disease
ASC adipose-derived stem/stroma cell
ECM extracellular matrix
YAP Yes-associated protein
hs-CRP high-sensitivity C-reactive protein
iNOS inducible nitric oxide synthase
SRA class A scavenger receptor
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